Secukinumab for plaque psoriasis with ocular comorbidity: a clinical experience

Abstract

Psoriasis is a systemic inflammatory disorder associated with many other chronic and progressive diseases. Ocular comorbidity has been reported in 10–15% of patients with plaque psoriasis, but the real incidence is still underestimated. This paper reports successful treatment with secukinumab of a patient with plaque psoriasis and dry eye syndrome. Secukinumab treatment was rapidly effective on skin psoriasis and this result was in agreement with observations reported in the literature. Interestingly, both the skin condition and the ocular disease improved after treatment. Our experience suggests that this drug should be used in patients with plaque psoriasis and ophthalmologic manifestations.

KEYWORDS:

• Psoriasis
• dry eye syndrome
• secukinumab

Acknowledgments

Laura Brogelli, PhD, on behalf of Content Ed Net, provided editorial assistance for the preparation of this manuscript which was funded by Novartis Farma Italy.

Disclosure statement

The authors have no conflict of interest to declare.

Additional information

Funding

This supplement was funded by Novartis.